{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:02:00Z","timestamp":1785542520799,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","revespcardiol.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.rec.2017.05.036","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T01:45:50Z","timestamp":1504316750000},"page":"991-1004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope"],"prefix":"10.1016","volume":"70","author":[{"given":"Esther","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"L\u00f3pez-Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2017.05.036_bib0270","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","article-title":"Amiloidosis. Tambi\u00e9n una enfermedad del coraz\u00f3n","volume":"64","author":"Garc\u00eda-Pav\u00eda","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rec.2017.05.036_bib0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.rec.2017.05.036_bib0280","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2017.05.036_bib0285","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0290","first-page":"9","article-title":"Epidemiology of transthyretin associated familial amyloid polyneuropathy in the Majorcan area: Son Ll\u00e0tzer Hospital descriptive study","author":"Rein\u00e9s","year":"2014","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.rec.2017.05.036_bib0295","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart."},{"key":"10.1016\/j.rec.2017.05.036_bib0300","doi-asserted-by":"crossref","first-page":"e003352","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.rec.2017.05.036_bib0305","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.rec.2017.05.036_bib0315","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2017.05.036_bib0320","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.rec.2017.05.036_bib0325","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2017.05.036_bib0330","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2017.05.036_bib0335","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2017.05.036_bib0340","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2017.05.036_bib0345","doi-asserted-by":"crossref","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0350","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0355","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2017.05.036_bib0360","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2017.05.036_bib0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amylodosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0370","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/heartjnl-2012-302346","article-title":"Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease","volume":"98","author":"Sado","year":"2012","journal-title":"Heart."},{"key":"10.1016\/j.rec.2017.05.036_bib0375","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.recesp.2016.02.032","article-title":"El volumen extracelular detecta la amiloidosis cardiaca y est\u00e1 correlacionado con el deterioro neurol\u00f3gico en la amiloidosis familiar relacionada con la transtiretina","volume":"69","author":"Gallego-Delgado","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0380","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0002-8703(82)90344-1","article-title":"Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy","volume":"103","author":"Sobol","year":"1982","journal-title":"Am Heart J."},{"key":"10.1016\/j.rec.2017.05.036_bib0385","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0390","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.recesp.2011.12.015","article-title":"Papel de la gammagraf\u00eda cardiaca con 99mTc-DPD en la discriminaci\u00f3n del subtipo de amiloidosis cardiaca","volume":"65","author":"De Haro-del Moral","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0400","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0405","doi-asserted-by":"crossref","first-page":"e002954","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2017.05.036_bib0410","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.recesp.2016.01.039","article-title":"Amiloidosis cardiaca detectada mediante PET\/TC con 18F-florbetapir","volume":"69","author":"Garc\u00eda-Gonz\u00e1lez","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.recesp.2010.10.018","article-title":"Abordaje familiar en la amiloidosis cardiaca hereditaria por transtiretina","volume":"64","author":"Garc\u00eda-Pav\u00eda","year":"2011","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.medcli.2015.02.003","article-title":"Recomendaciones para el diagn\u00f3stico y tratamiento de la polineuropat\u00eda amiloid\u00f3tica familiar por transtireina","volume":"145","author":"Garc\u00eda-Pav\u00eda","year":"2015","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.rec.2017.05.036_bib0425","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2017.05.036_bib0430","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa013354","article-title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis","volume":"346","author":"Lachmann","year":"2002","journal-title":"N Engl J Med."},{"issue":"sup1","key":"10.1016\/j.rec.2017.05.036_bib0435","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","article-title":"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?","volume":"24","author":"Aus dem Siepen","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2017.05.036_bib0440","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.rec.2017.05.036_bib0445","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rec.2017.05.036_bib0450","unstructured":"World Transplant Registry and Domino Liver Transplant Registry [Accessed 16 May 2017]. Available at: http:\/\/www.fapwt.org."},{"key":"10.1016\/j.rec.2017.05.036_bib0455","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2017.05.036_bib0460","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis."},{"issue":"Suppl 1","key":"10.1016\/j.rec.2017.05.036_bib0465","first-page":"19","article-title":"Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement","volume":"19","author":"Adams","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rec.2017.05.036_bib0470","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/13506129.2017.1280015","article-title":"Treatment of transthyretin cardiomyopathy with a TTR specific antisense oligonucleotide (IONIS-TTRRx)","volume":"24 sup 1","author":"Benson","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2017.05.036_bib0475","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.rec.2017.05.036_bib0480","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res."},{"key":"10.1016\/j.rec.2017.05.036_bib0485","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.rec.2017.05.036_bib0490","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.rec.2017.05.036_bib0495","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail."},{"key":"10.1016\/j.rec.2017.05.036_bib0500","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat Commun."},{"key":"10.1016\/j.rec.2017.05.036_bib0505","series-title":"The XVth International Symposium on Amyloidosis","article-title":"Doxycycline treatment of amyloidosis: a phase II study","author":"Berk","year":"2016"},{"issue":"sup1","key":"10.1016\/j.rec.2017.05.036_bib0510","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycicline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2017.05.036_bib0515","series-title":"The XVth International Symposium on Amyloidosis","article-title":"A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis","author":"Obici","year":"2016"},{"key":"10.1016\/j.rec.2017.05.036_bib0520","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"Aus dem Siepen","year":"2015","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.rec.2017.05.036_bib0525","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid."},{"key":"10.1016\/j.rec.2017.05.036_bib0530","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585717303857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585717303857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T22:33:06Z","timestamp":1570055586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585717303857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1885585717303857"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2017.05.036","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2017.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2017.05.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}